Search research articles
Contact Us
Filters
Showing results (491-500 of 744) with videos related to
Page
of 75
Sort By:
Swiss Medical Weekly
|
August 14, 2025
The updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma
Johanna Mangana, Berna C Özdemir, Daniela Mihic-Probst, et al.
Cancer Research
|
November 5, 2015
Nrf2 Activation Promotes Keratinocyte Survival during Early Skin Carcinogenesis via Metabolic Alterations
Frank Rolfs, Marcel Huber, Andreas Kuehne, et al.
Pharmacology Research & Perspectives
|
March 3, 2015
A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma
Simone M Goldinger, Jeannine Rinderknecht, Reinhard Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 24, 2019
Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology
Lucie Heinzerling, Paolo A Ascierto, Reinhard Dummer, et al.
Journal for Immunotherapy of Cancer
|
June 21, 2022
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
Hussein A Tawbi, Caroline Robert, Jan C Brase, et al.
Journal of the American Academy of Dermatology
|
July 16, 2013
Phototherapy with UVB narrowband, UVA/UVBnb, and UVA1 differentially impacts serum 25-hydroxyvitamin-D3
Laurence Feldmeyer, Golnar Shojaati, Katharina-Susanne Spanaus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 13, 2009
Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group
Andrew Bottomley, Corneel Coens, Stefan Suciu, et al.
Nature Communications
|
August 21, 2021
Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4
Johanna Diener, Arianna Baggiolini, Mattias Pernebrink, et al.
JCI Insight
|
February 6, 2024
Differential histone acetylation and super-enhancer regulation underlie melanoma cell dedifferentiation
Karen Mendelson, Tiphaine C Martin, Christie B Nguyen, et al.
British Journal of Cancer
|
June 18, 2021
Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies
Sebastian Bauer, George D Demetri, Ensar Halilovic, et al.
Page
of 75
Search research articles
Search
Showing results (491-500 of 744) with videos related to
Sort By:
Page
of 75
Swiss Medical Weekly
|
August 14, 2025
The updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma
Johanna Mangana, Berna C Özdemir, Daniela Mihic-Probst, et al.
Cancer Research
|
November 5, 2015
Nrf2 Activation Promotes Keratinocyte Survival during Early Skin Carcinogenesis via Metabolic Alterations
Frank Rolfs, Marcel Huber, Andreas Kuehne, et al.
Pharmacology Research & Perspectives
|
March 3, 2015
A single-dose mass balance and metabolite-profiling study of vemurafenib in patients with metastatic melanoma
Simone M Goldinger, Jeannine Rinderknecht, Reinhard Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 24, 2019
Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology
Lucie Heinzerling, Paolo A Ascierto, Reinhard Dummer, et al.
Journal for Immunotherapy of Cancer
|
June 21, 2022
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)
Hussein A Tawbi, Caroline Robert, Jan C Brase, et al.
Journal of the American Academy of Dermatology
|
July 16, 2013
Phototherapy with UVB narrowband, UVA/UVBnb, and UVA1 differentially impacts serum 25-hydroxyvitamin-D3
Laurence Feldmeyer, Golnar Shojaati, Katharina-Susanne Spanaus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 13, 2009
Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group
Andrew Bottomley, Corneel Coens, Stefan Suciu, et al.
Nature Communications
|
August 21, 2021
Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4
Johanna Diener, Arianna Baggiolini, Mattias Pernebrink, et al.
JCI Insight
|
February 6, 2024
Differential histone acetylation and super-enhancer regulation underlie melanoma cell dedifferentiation
Karen Mendelson, Tiphaine C Martin, Christie B Nguyen, et al.
British Journal of Cancer
|
June 18, 2021
Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies
Sebastian Bauer, George D Demetri, Ensar Halilovic, et al.
Page
of 75